Abstract

The clinical management of cervical cancer in HIV-positive patients has challenges mainly due to the concerns on immune status. At present, their mode of management is similar to HIV-seronegative patients involving the use of chemotherapy and radiotherapy concurrently as indicated. HIV infection, cancer, radiotherapy, and chemotherapy lower immunity through reduction in CD4 cell counts. At present there are no treatment guidelines for HIV-positive patients. This study was done to systematically review the literature on cervical cancer management in HIV-positive patients and treatment outcomes. A systematic literature search was done in the major databases to identify studies on the management of HIV-positive patients with cervical cancer. Identified studies were assessed for eligibility and inclusion in the review following the guidelines of The Cochrane Handbook for Systematic Reviews and CRD's (Centre for Reviews and Dissemination) guidance for undertaking reviews in health care. Eight eligible studies were identified from the literature. Three of them were prospective while five were retrospective studies. Notably, the average age at diagnosis of cervical cancer in HIV-positive patients was a decade lower than in seronegative patients. There was no difference in distribution of stages of disease at presentation between HIV-positive and negative patients. Mild acute toxicity (Grades 1 and 2) was higher in HIV-positive patients than in HIV-negative patients in hematopoietic system. In the grades 3 and 4 reactions, anemia was reported in 4% versus 2% while gastrointestinal reactions were reported in 5% versus 2% respectively. In general, patients who were started early on HAART had higher rates of treatment completion. The study supports the suggestion that HAART should be commenced early at cervical cancer diagnosis in HIV-positive patients diagnosed with cervical cancer to ensure less toxicity and better treatment compliance.

Highlights

  • Cancer of the uterine cervix is the most common gynecological malignancy and occurs worldwide [1]

  • This systematic review summarized available evidence regarding the treatment of cervical cancer patients with HIV infection treated with chemo-­radiotherapy which is a mode of treating cervical cancer recommended by many

  • This review shows that median age of HIV-­positive cervical cancer patients was at least a decade lower than in their HIV-­negative counterparts (40 years vs. 52 years)

Read more

Summary

Introduction

Cancer of the uterine cervix is the most common gynecological malignancy and occurs worldwide [1]. It has been reported that about eighty percent of cervical cancers occur in the developing countries [2]. The most important risk factor for the development of cervical cancer is the human papilloma virus (HPV) [5]. Cervical cancer is very common in HIV-­seropositive patients with an aggressive course and poor treatment outcome [6]. Regions of high prevalence of cervical cancer correspond with regions of high prevalence of HIV infection [7]. Cervico-­vaginal HPV infection has been reported to be higher in HIV-p­ositive women than in their HIV-­negative counterparts.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call